Salt Lake City-based Amedica filed a registration statement on Form S-1 related to a proposed public offering of its securities.
Amedica is focused on developing silicon nitride ceramics as a material platform to manufacture and commercialize orthopedic implants.
Here are five things to know about the IPO:
1. The registration statement has been filed, but has not yet become effective. The securities may not be sold and no offers to buy will be accepted until the registration statement is effective.
2. The company expects to offer share units of common stock and warrants to purchase shares of common stock.
3. Dawson James Securities is acting as the sole book-running manager for the offering.
4. The number of units that will be offered and terms of the units are not yet determined.
5. Those interested may acquire a preliminary prospectus from Dawson James Securities when they are made available by emailing mmaclaren@dawsonjames.com.
The company also recently announced a private labeling agreement with Spinal Kinetics where the company will provide Spinal Kinetics with sterile packed silicon nitride spinal interbody fusion devices for sale in worldwide markets.
More articles on orthopedic devices:
Stryker hip implant settlement to exceed $1.4B—10 key facts
Orthopedic device market stock report—5 company updates
Alphatec Spine 3Q revenue up 2%: 10 key concepts